The FDA Has Already Authorized Clinical Trials Into the Therapeutic Potential of MDMA for Patients With PTSD, But Now it’s Given the Green Light to a Psychedelics Research Institute to Expand its Studies By Administering the Substance to Certain Therapists
Volunteer therapists who are being trained to treat people with PTSD will be able to participate in the Phase 1 trials to gain personal experience with the treatment option. This is a complementary research project that comes as the Multidisciplinary Association for Psychedelic Studies (MAPS) is in the process of conducting Phase 3 trials involving people with the disorder.